Brisbane, Australia, 23 August 2019 – ResApp Health Limited (ASX:RAP), a leading digital healthcompany developing smartphone applications for the diagnosis and management of respiratorydisease, today announced that its first commercial product, ResAppDx-EU, has received CE Markcertification as a Class IIa medical device. ResAppDx-EU is the world’s first smartphone-baseddiagnostic test for acute paediatric respiratory disease. CE Mark certification indicates thatResAppDx-EU meets the essential requirements of all the applicable European regulations as amedical device and allows for the sale of ResAppDx-EU in the European Economic Area.
RAP Price at posting:
15.0¢ Sentiment: Hold Disclosure: Held
